Breaking News, Promotions & Moves

Oryon Cell Therapies Appoints Dr. Burkhard Blank as Chief Medical Officer

The veteran drug development leader brings extensive global experience.

Author Image

By: Charlie Sternberg

Associate Editor

Oryon Cell Therapies, a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, has appointed Burkhard Blank, M.D., as Chief Medical Officer (CMO). “Burkhard is a highly accomplished drug developer whose experience spans the full arc of bringing innovative therapies from concept to approval,” said Ron Cohen, M.D., CEO of Oryon. “During his tenure as CMO at Acorda Therapeutics, I saw his o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters